Long-term effects of spironolactone in peritoneal dialysis patients

Yasuhiko Ito, Masashi Mizuno, Yasuhiro Suzuki, Hirofumi Tamai, Takeyuki Hiramatsu, Hiroshige Ohashi, Isao Ito, Hirotake Kasuga, Masanobu Horie, Shoichi Maruyama, Yukio Yuzawa, Tatsuaki Matsubara, Seiichi Matsuo, M. Watanabe, H. Nishimura, M. Mizutani, H. Kinashi, A. Dambara, Y. Saka, S. TodaS. Kimu, K. Minoshima, M. Yamaha, R. Takahashi, K. Kimura, T. Naruse, T. Matsuoka, D. Inaguma, K. Kurata

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

ESRD treated with dialysis is associated with increased left ventricular hypertrophy, which, in turn, is related to highmortality.Mineralocorticoid receptor antagonists improve survival in patients with chronic heart failure; however, the effects in patients undergoing dialysis remain uncertain. We conducted a multicenter, open-label, prospective, randomized trial with 158 patients receiving angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist and undergoing peritoneal dialysis with and without (control group) spironolactone for 2 years. As a primary endpoint, rate of change in left ventricular mass index assessed by echocardiography improved significantly at 6 (P=0.03), 18 (P=0.004), and 24 (P=0.01) months in patients taking spironolactone compared with the control group. Rate of change in left ventricular ejection fraction improved significantly at 24 weeks with spironolactone compared with nontreatment (P=0.02). The benefits of spironolactone were clear in patients with reduced residual renal function. As secondary endpoints, renal Kt/V and dialysate-to-plasma creatinine ratio did not differ significantly between groups during the observation period. No serious adverse effects, such as hyperkalemia, occurred. In this trial, spironolactone prevented cardiac hypertrophy and decreases in left ventricular ejection fraction in patients undergoing peritoneal dialysis, without significant adverse effects. Further studies, including those to determine relative effectiveness in women and men and to evaluate additional secondary endpoints, should confirm these data in a larger cohort.

Original languageEnglish
Pages (from-to)1094-1102
Number of pages9
JournalJournal of the American Society of Nephrology
Volume25
Issue number5
DOIs
Publication statusPublished - 01-05-2014

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Ito, Y., Mizuno, M., Suzuki, Y., Tamai, H., Hiramatsu, T., Ohashi, H., Ito, I., Kasuga, H., Horie, M., Maruyama, S., Yuzawa, Y., Matsubara, T., Matsuo, S., Watanabe, M., Nishimura, H., Mizutani, M., Kinashi, H., Dambara, A., Saka, Y., ... Kurata, K. (2014). Long-term effects of spironolactone in peritoneal dialysis patients. Journal of the American Society of Nephrology, 25(5), 1094-1102. https://doi.org/10.1681/ASN.2013030273